Highlights of PCORI-Funded Research Results


Cropped shot of a caretaker giving medication and a glass of water to a patient

Adults with cancer who took a newer oral blood thinner to prevent recurrent venous thromboembolism (VTE), or blood clots, fared just as well as those who took an older injectable blood thinner, according to PCORI-funded study results published in JAMA this month.

The CANVAS Trial—led by Deborah Schrag, MD, MPH, at the Alliance for Clinical Trials in Oncology Foundation—compared the effectiveness of direct oral anticoagulants (DOACs) with injectable low-molecular-weight heparin (LMHW) among 638 adults with cancer at 67 sites.

Following a six-month treatment period, the study team found that DOAC treatment was noninferior to LMHW treatment for preventing recurrent VTE. In addition, there were no significant differences between the two groups in bleeding, mortality, serious adverse events, quality of life, or burden and benefits of medication.

Posted: June 12, 2023

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.

Subscribe to PCORI Emails


Hand pointing to email icon